# NAUTIKA 1 (NCT04302025)

> A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04302025
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Non-small Cell Lung Cancer
- Interventions: Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib
- Enrollment: 99
- Primary outcome: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
- Primary outcome: Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)
- Primary outcome: KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)
- Primary outcome: KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the Investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 25
- YouTube: 24
- Podcasts: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nautika-1-nct04302025

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04302025", "email": "<work email>"}; the inbox owner confirms by the emailed link.